List view / Grid view
Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.
22 July 2016 | By Victoria White, Digital Content Producer
Drug Target Review recently caught up with Lorence Kim, Chief Financial Officer of Moderna, to find out more about the company‘s collaboration with Vertex and using mRNA therapeutics to treat patients with cystic fibrosis...
6 July 2016 | By Victoria White, Digital Content Producer
Their collaboration will focus on the use of mRNA therapies to enable cells in the lungs to produce functional copies of the CFTR protein...
19 April 2016 | By Victoria White, Digital Content Producer
Enterome has signed a license agreement with Vertex to research, develop and commercialise novel small molecule FimH antagonists...
4 January 2016 | By Victoria White
Vertex Pharmaceuticals is to use Genomic’s integrated database and state-of-the-art analysis tools to identify target therapeutic pathways...
26 October 2015 | By Victoria White
The collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases, including cystic fibrosis, where targets have been validated through human genetics...
20 April 2015 | By Oxford Global
Oxford Global is proud to present its 16th Annual Drug Discovery Summit and the co-located 3rd Annual Discovery Chemistry & Drug Design Congress taking place in Berlin on the 8th and 9th of June 2015...
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787...
